Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma (PET Chop)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2011 by AHS Cancer Control Alberta.
Recruitment status was:  Active, not recruiting
Hoffmann-La Roche
Information provided by (Responsible Party):
Rachel Syme, Alberta Health Services Identifier:
First received: September 13, 2007
Last updated: December 6, 2011
Last verified: August 2011

The purpose of this study is to evaluate:

  1. whether an imaging test called a PET (Positron emission tomography) scan performed after two cycles of standard chemotherapy is able to identify patients who have a high cure rate after completing standard chemotherapy alone; and
  2. whether high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) when used in combination with an antibody called Rituximab results in high cure rates for those patients predicted to do poorly with standard chemotherapy by the PET scan.

Condition Intervention
Diffuse Large B Cell Lymphoma
Procedure: Autologous Blood Stem Transplantation
Drug: R-CHOP (Rituximab, Cyclphosphamide, Etoposide, Cisplatin, Mesna, G-CSF

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: FDG-PET-Stratified R-DICEP and R-BEAM/ASCT For Diffuse Large B-Cell Lymphoma

Resource links provided by NLM:

Further study details as provided by AHS Cancer Control Alberta:

Estimated Enrollment: 80
Study Start Date: July 2007
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm A
Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined negative for disease intensity patient receives 4 more cycles R-CHOP (total 6 cycles R-CHOP)
Drug: R-CHOP (Rituximab, Cyclphosphamide, Etoposide, Cisplatin, Mesna, G-CSF
6 - 21 DAY Cycles of R-CHOP
Active Comparator: Arm B
Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined positive for disease intensity the patient receives one cycle or R-DICEP/R-BEAM the autologous blood stem cell transplantation.
Procedure: Autologous Blood Stem Transplantation


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18-65 years
  • Diagnosis of Diffuse Large B-Cell Lymphoma
  • Adverse Prognosis = Stage 3 or 4 and elevated LDH
  • No more than one prior cycle of R-CHOP chemotherapy
  • Adequate cardiac function
  • No central nervous system involvement by lymphoma

Exclusion Criteria:

  • Histological diagnosis other than Diffuse Large B-cell Lymphoma
  • Pregnant or lactating females
  • Use of other anti-cancer therapies
  • Other serious illness that would compromise study participation
  • Prior malignancy
  • Prior stem cell transplant or radiotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00530179

Canada, Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T4C 2H5
Canada, Ontario
Ottawa General Hospital
Ottawa, Ontario, Canada, K1H 8L6
Canada, Saskatchewan
Saskatchewan Cancer Agency
Regina, Saskatchewan, Canada, S7N 4H4
Sponsors and Collaborators
Alberta Health Services
Hoffmann-La Roche
Principal Investigator: Douglas Stewart, M.D. AHS Cancer Control Alberta
  More Information

Responsible Party: Rachel Syme, Dr. Douglas Stewart - Principal Investigator, Alberta Health Services Identifier: NCT00530179     History of Changes
Other Study ID Numbers: 0307003
Study First Received: September 13, 2007
Last Updated: December 6, 2011

Keywords provided by AHS Cancer Control Alberta:
Diffuse Large B-Cell Lymphoma
Positron Emission Tomography
CHOP Chemotherapy protocol
Stem Cell Transplantation
Fluorodeoxyglucose F18

Additional relevant MeSH terms:
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 22, 2017